Next year, the US Food and Drug Administration (FDA) is forecast to approve the highest number of novel drugs for at least ten years, a new analysis of Evaluate Pharma data shows. The forecast 2025 total of 74 is higher even than last year’s total of 73, itself the highest since at least 2016. (Also see "Steady On For US FDA’s Novel Approvals At Mid-Year, But Another 2023 Is Unlikely" - Pink Sheet, 18 July, 2024.)
US Approvals Of Novel Drugs Set To Hit 10-Year High In 2025
But 2024 will see a lull between two strong years.
More from Growth
More from In Vivo
• By
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
• By
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
• By
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.